All In Biotech

Drug Trial Radar · NCT03723395

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

A Phase 1, Open-Label, Fixed-sequence, 5-part, Drug-drug Interaction Study of Tucatinib to Evaluate the Effects of CYP3A4 and CYP2C8 Inhibition and Induction on the Pharmacokinetics of Tucatinib and to Evaluate the Effects of Tucatinib on the Pharmacokinetics of Substrates of CYP3A4, CYP2C8, CYP2C9, and P-glycoprotein in Healthy Male and Female Subjects

Last checked: Nov 20, 2026Latest source record: Dec 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

116

Actual

Start

Sep 17, 2018

Primary completion

Dec 21, 2018

Study completion Dec 28, 2018

Sponsor

Lead sponsor
Seagen Inc.Pfizer (PFE)
Sponsor type
Industry
First posted
Oct 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is being done to look at how tucatinib could affect the way other drugs work. This study will look at healthy volunteers and how tucatinib affects their liver enzymes. Liver enzymes can change how drugs work in the body. There are 5 parts to this study. Parts A and C are looking at how the body breaks down tucatinib when there are lower levels of certain liver enzymes. Part B is looking at how the body breaks down tucatinib when there are high levels of certain liver and stomach enzymes. Parts D and E are looking at how tucatinib could change the levels of some liver and stomach enzymes in the body. This will help us know more about how tucatinib should be given to patients.

Conditions

  • Drug-drug Interaction

Interventions

  • tucatinibDrug

    300mg dose, orally administered

  • itraconazoleDrug

    200mg dose

  • rifampinDrug

    600mg dose

  • gemfibrozilDrug

    600mg tablets

  • repaglinideDrug

    1mg dose

  • tolbutamideDrug

    500mg dose

  • midazolamDrug

    2mg dose

  • digoxinDrug

    0.5 mg dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration-time curve (AUC) from time 0 to infinityTime frame: Up to 22 days
  2. AUC from time 0 to the time of the last quantifiable concentrationTime frame: Up to 22 days
  3. Percentage extrapolation in AUCTime frame: Up to 22 days
  4. Maximum observed concentrationTime frame: Up to 22 days
  5. Time of maximum observed concentrationTime frame: Up to 22 days
  6. Apparent terminal elimination half-lifeTime frame: Up to 22 days
  7. Apparent total clearanceTime frame: Up to 22 days
  8. Apparent volume of distributionTime frame: Up to 22 days
  9. Metabolite-to-parent ratio based on AUCTime frame: Up to 22 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Covance Clinical Research Unit

    Daytona Beach, Florida

  • Covance Clinical Research Unit

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.